Mar 07, 2022 / 02:10PM GMT
Ken Cacciatore - Cowen and Company, LLC - Analyst
Great. Thanks so much, David, for putting us in. And Karim, thanks for joining us. It's really great to have you, a real exciting time. And I know there's been a lot of exciting times, maybe too many exciting times for Amarin, but we are truly on the cusp of one now. And there has never been any doubt about really the quality of the product and the good that this product can do for patients.
It's clearly been more business issues and legal issues that have kind of constrained the valuation, and to a certain extent, maybe, constrained in getting this product to patients, which is a little bit sad.
Questions and Answers:
Ken Cacciatore - Cowen and Company, LLC - AnalystSo we want to talk about all of it. And I believe you are joining us from Europe, and that's exactly where we wanted to start. So you're physically -- and in the location we'd want to kind of begin the conversation. So for us here at Cowen, obviously, Europe is a key component, too, when we look at the value of Amarin, one of the
Trustpilot
